Dr. Mark Mofid is a plastic surgeon serving clients in San Diego and La Jolla. He has certification from the the American Board of Plastic Surgery (ABPS) and the American Board of Facial Plastic and Reconstructive Surgery (AAFPRS). Dr. Mofid’s practice is located in La Jolla.
Mark Mofid graduated from Harvard University with honors. At The Johns Hopkins University Medical School, he studied for his MD, trained in general and plastic surgery, and completed a fellowship in craniofacial research. Some of his hospital affiliations are Scripps Memorial Hospital, Sharp Chula Vista Medical Center, and Palomar Medical Center.
Mark is a professor of Plastic Surgery at UC San Diego. Mr. Mark Mofid has been featured on the Plastic and Reconstructive Surgery journal. He provides reconstructive surgery to his patients (e.g. breast and facial reconstruction,microsurgery, facial repairs, etc.).
Mofid uses intramuscular implants for buttock augmentation. He does not use large implants for patients because they have a high palpability rate, incision opening, and malposition. Gravity causes malposition. Dr. Mofid discovered that silicone implants have offered defective buttocks. They were oversized for intramuscular placements. Mofid had to spend time cutting down the implants prior surgeries.
Mark Mofid created a Low Profile Round Gluteal Implant for Implantech. Due to its “tapered profile”, intramuscular positioning is simpler and base width-to-volume ratio is improved. This results in greater proportionality. Implatech does not pay any royalties to Mofid. Dr. Raul Gonzalez, a Brazilian plastic surgeon, influenced Mofid’s butt augmentation method. Mofid is one of the few American surgeons to be highly trained in butt augmentation. He found out that each Playboy magazine centerfold from 1953 and beyond had a waist-to-hip ratio of 0.68.
Dr. Mark Mofid learned about fat and tissue excision by performing blepharoplasties. Dr. Mofid was the first surgeon to reveal midface endoscopic surgery in Aesthetic Plastic Surgery. Mofid has previously made presentations and publications on revisionary cosmetic surgery with Acellular Dermal Matrix (ADM) products. Now, he has moved away from biologics since they require tracking and refrigeration. Also, their manufacturing cost is high. ADM products have higher seroma and infection rates.